An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adaptive Biotechnologies (Nasdaq: ADPT) will report its first quarter 2024 financial results on May 7, 2024. The company aims to translate adaptive immune system genetics into clinical products for disease diagnosis and treatment. The webcast of the conference call will be available on the company's website.
Adaptive Biotechnologies (Nasdaq: ADPT) pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024. L'azienda si propone di trasformare la genetica del sistema immunitario adattativo in prodotti clinici per la diagnosi e il trattamento delle malattie. La trasmissione web della conferenza telefonica sarà disponibile sul sito web dell'azienda.
Adaptive Biotechnologies (Nasdaq: ADPT) informará sobre sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La compañía tiene como objetivo traducir la genética del sistema inmunitario adaptativo en productos clínicos para el diagnóstico y tratamiento de enfermedades. La transmisión web de la llamada de conferencia estará disponible en el sitio web de la compañía.
Adaptive Biotechnologies (Nasdaq: ADPT)는 2024년 5월 7일에 2024년 1분기 재무 결과를 보고할 예정입니다. 이 회사는 적응 면역 체계 유전학을 질병 진단 및 치료를 위한 임상 제품으로 변환하는 것을 목표로 합니다. 회의 전화의 웹캐스트는 회사 웹사이트에서 볼 수 있습니다.
Adaptive Biotechnologies (Nasdaq: ADPT) publiera ses résultats financiers pour le premier trimestre 2024 le 7 mai 2024. L'entreprise vise à transformer la génétique du système immunitaire adaptatif en produits cliniques pour le diagnostic et le traitement des maladies. La webdiffusion de la conférence téléphonique sera disponible sur le site web de l'entreprise.
Adaptive Biotechnologies (Nasdaq: ADPT) wird am 7. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen beabsichtigt, die Genetik des adaptiven Immunsystems in klinische Produkte zur Krankheitsdiagnose und -behandlung umzusetzen. Die Webübertragung des Konferenzanrufs wird auf der Website des Unternehmens verfügbar sein.
Positive
None.
Negative
None.
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE MEDIA Erica Jones, Associate Director, Corporate Communications 206-279-2423 media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies report its first quarter 2024 financial results?
Adaptive Biotechnologies will report its first quarter 2024 financial results on May 7, 2024.
What is the ticker symbol for Adaptive Biotechnologies?
The ticker symbol for Adaptive Biotechnologies is ADPT.
Where can I listen to the webcast of the conference call for Adaptive Biotechnologies?
You can listen to the webcast of the conference call for Adaptive Biotechnologies on the 'Investors' section of the company website at www.adaptivebiotech.com.
we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and
